Depomed is a pharmaceutical company focused on pain and other central nervous system conditions. Co.'s business includes the following products marketed in the U.S. for various pain states: Gralise®, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA®, which is a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; Zipsor®, which is a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain; NUCYNTA® ER, which is a product for the management of pain severe enough to require daily, including neuropathic pain; and NUCYNTA® IR, which is for the management of moderate to severe acute pain in adults. The DEPO average annual return 10 years is shown above.
The Average Annual Return on the DEPO average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether DEPO average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the DEPO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|